deep state solution to oncy's buyout conundrumInstead of waiting for some "strap-on" godemiche from big pharma, and in light of the U.S. effort to prevent the Chinese from obtaining/controlling various aspects of biotech intellectual property, Matt could reach our for a high-dollar deal for the U.S. market and keep his toy for whatever it is he chooses to do with Oncy and his career aspirations down the road.
What would a $2 billion dollar deal for pela in the U.S. market do for Onc/Oncy's stock price? No milestone payments or other complications, just a high enough right to pela in the U.S. without any other types of payout complications down the road.
The U.S. Department of Health and Human Services has a proposed 2023 budget of $127.3 billion in discretionary and $1.7 trillion in mandatory budget authority.
Their mission statement is to enhance the health and well-being of all Americans (let's ignore the fact that our neighbors to the north are also "north" Americans), by providing for effective health and human services and by fostering sound, sustained advances and the sciences underlying medicine, public health, and social services.
The Department leverages resouces from various other governmental organizations to enable HHS to accomplish ist mission through strategies that minimize the burden on, and increase the benefits to, the American public.
The FDA has already granted fast track status and if DHHS were to be in the picture the opportunity to work collaboratively getting pela to market in various combo treatments would certainly be enhanced.
Cancer is the second leading cause of death in the United States. Each year in the United States, more than 1.7 million people are diagnosed with cancer, and almost 600,000 die from it, making it the nation's second leading cause of death.
Controlling Pelareorep in the U.S. would give the government a leg up in negotiating the price of combo therapies with BP thereby helping to curb the insane increase in the cost of healthcare.
Not sure where pela is being manufactured but any deal could certainly include the right to manufacture for the U.S. market right here in the U.S.
View this through the lens of the Chrysler bailout. Healthcare is in need of help and controlling pela for use in the treatment of various cancers would certainly be a proposition with positive payback.
Pela could be the first asset in a healthcare "U.S. sovereign wealth fund" in which the public gets the dividend payments through a reduced healthcare burden on the U.S. debt.